1. In Vivo
  2. >>Global Vision

Times Of Unprecedented Change: German Medtech Readies For Challenging 2024

Hospital Payment Reforms, Digital Strategy, Place-Based Care On The German Agenda

 
• By Ashley Yeo

German medtech and health care are going through a period of unprecedented change and modernization, with hospital reform on the agenda and integration of digitized functionality happening across the sector. The EU Medical Device Regulation casts a long shadow over the medtech industry and will result in a shake out among companies and products, as In Vivo learnt at Medica 2023.

Shutterstock

Digital prescriptions on smart phones had a soft roll out in Germany in July 2023 and since 1 January 2024 have been a standard offering at all pharmacies. The public can now access prescribed medication via a smartphone app, the gematik electronic Health Card (eGK) or may still use the paper option.

Local media reported teething troubles among community doctors struggling to master and integrate e-prescriptions into already full working days. Nevertheless, increased digital health care integration is a top priority for Germany’s health minister, Karl Lauterbach

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

 
• By Brian Yang

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

More from In Vivo

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.